19427-36-2 Usage
Uses
Used in Pharmaceutical Industry:
11a-Hydroxy-16,17a-epoxyprogesterone is utilized as a pharmaceutical agent for its ability to induce maturation and secretory activity of the uterine endothelium. This makes it a valuable component in treatments related to the reproductive system, particularly in managing menstrual disorders and promoting a healthy uterine environment.
Additionally, this steroid hormone is used as a suppressant of ovulation, which can be beneficial in contraceptive applications or in the management of conditions that involve hormonal imbalances.
Used in Cancer Research:
Due to its structural similarity to progesterone and its implication in the etiology of breast cancer, 11a-Hydroxy-16,17a-epoxyprogesterone serves as a crucial compound in cancer research. It aids scientists in understanding the complex interactions between hormones and cancer development, potentially leading to the discovery of novel therapeutic approaches and preventive strategies for breast cancer and possibly other hormone-related cancers.
Synthesis
11a-Hydroxy-16,17a-epoxyprogesterone can be prepared from diosgenin through the steps of ring-opening, acetylation, oxidation, hydrolysis, elimination, epoxidation, and oxidation.
Check Digit Verification of cas no
The CAS Registry Mumber 19427-36-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,4,2 and 7 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 19427-36:
(7*1)+(6*9)+(5*4)+(4*2)+(3*7)+(2*3)+(1*6)=122
122 % 10 = 2
So 19427-36-2 is a valid CAS Registry Number.
InChI:InChI=1/C21H28O4/c1-11(22)21-17(25-21)9-15-14-5-4-12-8-13(23)6-7-19(12,2)18(14)16(24)10-20(15,21)3/h8,14-18,24H,4-7,9-10H2,1-3H3/t14-,15-,16+,17+,18+,19-,20-,21+/m0/s1
19427-36-2Relevant academic research and scientific papers
Preparation method of betamethasone intermediate
-
Paragraph 0072; 0076, (2017/02/24)
The invention relates to a preparation method of a steroid drug intermediate, and concretely relates to a preparation method of a betamethasone intermediate which is 16beta-methyl-17alpha-hydroxypregna-4,9-diene-3,20-dione. The method comprises the following steps: carrying out a cyanidation reaction on 9alpha-hydroxy-4-ene-pregna-3,17-dione, carrying out a ketal protection reaction, carrying out a double elimination reaction, carrying out an epoxy reaction, and carrying out a Grignard addition hydrolysis reaction to prepare the target product. The method is a brand preparation technology for producing the betamethasone intermediate, and has the characteristics of cheap and easily available initial raw material, simple operations of all above reactions, high yield, suitableness for industrial massive production, and realization of the yield and the quality reaching satisfactory levels.
